Cambridge Investment Research Advisors
CPRX icon

Cambridge Investment Research Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$242K Sell
9,761
-1,700
-15% -$40.5K ﹤0.01% 3487
2025
Q4 		$267K Buy
11,461
+676
+6% +$15.1K ﹤0.01% 3315
2025
Q3 		$212K Buy
10,785
+1,170
+12% +$24.1K ﹤0.01% 3435
2025
Q2 		$209K Sell
9,615
-10,353
-52% -$244K ﹤0.01% 3315
2025
Q1 		$484K Buy
+19,968
New +$450K ﹤0.01% 2468
2023
Q1 		– Sell
-21,457
Closed -$399K – 3171
2022
Q4 		$399K Buy
+21,457
New +$330K ﹤0.01% 2201

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Cambridge Investment Research Advisors's CPRX Position: Q1 2026 in Review

Cambridge Investment Research Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 15% in Q1 2026, selling an estimated $40.5K and leaving 9,761 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #3487.

Cambridge Investment Research Advisors first reported a position in CPRX in Q4 2022 and has held it in 6 quarters since. The position peaked at $484K in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Cambridge Investment Research Advisors held 9,761 shares of Catalyst Pharmaceutical worth $242K as of Q1 2026.
  • Cambridge Investment Research Advisors sold 1,700 Catalyst Pharmaceutical shares in Q1 2026, an estimated $40.5K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #3487 holding.
  • Cambridge Investment Research Advisors first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 6 quarters since.
  • Cambridge Investment Research Advisors's Catalyst Pharmaceutical position peaked at $484K in Q1 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.